EGFR and medullary thyroid gland carcinoma: For instance, vandetanib, a tyrosine kinase inhibitor targeting the RET, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), has been approved by FDA as a drug for medullary thyroid cancer.